Safety and Efficacy of ZM-02 Optogenetic Gene Therapy Clinical Study for Advanced Retinitis Pigmentosa (ASGCT 2025) - Apr 10, 2025 - Abstract #849; Pres time: May 13, 2025; 06:00 PM - 07:30 PM; Location: Poster Hall; P1 | "This trial indicated that ZM-02 has a notable safety and tolerability profile with no drug-related AEs. Efficacy results showed significant BCVA improvement, supported by MLTs, with an unexpected bonus in color perception. These findings suggest that ZM-02 holds promise in advanced RP treatment."
Clinical • Gene therapy • Metastases • CNS Disorders • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
|
|
Wenhui Zhou 1; Shiyi Yin 2; Haihan Zhang 3; Menghan Zhou 4; MOJTABA SHIRINZADEH 5; Jingyun Liu 6; SHEN YIN 7; Wenbin Wei 3
|